UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

British journal of dermatology (1951), 2012-11, Vol.167 (5), p.1153-1160

2012

Volltextzugriff (PDF)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

British journal of cancer, 2014-07, Vol.111 (2), p.292-299

2014

Volltextzugriff (PDF)

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor

Oncogene, 2014-02, Vol.33 (9), p.1158-1166

2014

Volltextzugriff (PDF)

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma

British journal of cancer, 2013-03, Vol.108 (4), p.924-931

2013

Volltextzugriff (PDF)

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Annals of oncology, 2017-05, Vol.28 (5), p.1130-1136

2017

Volltextzugriff (PDF)

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients

Annals of oncology, 2019-05, Vol.30 (5), p.815-822

2019

Volltextzugriff (PDF)

Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series

Internal medicine journal, 2015-10, Vol.45 (10), p.1066-1073

2015

Volltextzugriff (PDF)

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

Oncoimmunology, 2016-09, Vol.5 (9), p.e1214788-e1214788

2016

Volltextzugriff (PDF)

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma

Oncogene, 2014-01, Vol.33 (2), p.236-245

2014

Volltextzugriff (PDF)

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma

British journal of cancer, 2009-04, Vol.100 (8), p.1245-1249

2009

Volltextzugriff (PDF)

Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma : A consensus statement of the melanoma genetics consortium

Journal of clinical oncology, 1999-10, Vol.17 (10), p.3245-3251

1999

Volltextzugriff (PDF)

Adjuvant therapy of cutaneous melanoma: the interferon debate

Annals of oncology, 2003-03, Vol.14 (3), p.358-365

KEFFORD, R. F

2003

Volltextzugriff (PDF)

Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization

Oncogene, 2000-06, Vol.19 (26), p.2978-2985

2000

Volltextzugriff (PDF)

Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure

Journal of the European Academy of Dermatology and Venereology, 2019-10, Vol.33 (10), p.1874-1885

2019

Volltextzugriff (PDF)

Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding

Clinical cancer research, 2001-10, Vol.7 (10), p.3282-3288

2001

Volltextzugriff (PDF)

Loss of Alleles from the Distal Short Arm of Chromosome 1 Occurs Late in Melanoma Tumor Progression

Proceedings of the National Academy of Sciences - PNAS, 1989-06, Vol.86 (12), p.4614-4618

1989

Volltextzugriff (PDF)

Long-term Survival and Occasional Regression of Distant Melanoma Metastases after Adrenal Metastasectomy

Annals of surgical oncology, 2008-06, Vol.15 (6), p.1741-1749

2008

Volltextzugriff (PDF)

A melanoma-associated germline mutation in exon 1β inactivates p14ARF

Oncogene, 2001-09, Vol.20 (39), p.5543-5547

2001

Volltextzugriff (PDF)

Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma

Oncogene, 1994-05, Vol.9 (5), p.1361-1365

1994

Volltextzugriff (PDF)

Cutaneous melanoma

Lancet, 2005-02, Vol.365 (9460), p.687-701

2005

Volltextzugriff (PDF)

CDKN2A (P16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas

Genes chromosomes & cancer, 1999-08, Vol.25 (4), p.339-348

1999

Volltextzugriff (PDF)

Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells

Cancer research (Baltimore), 1992-05, Vol.52 (9), p.2489-2496

1992

Volltextzugriff (PDF)

The WDNM1 gene product is a novel member of the ‘four-disulphide core’ family of proteins

Biochemical and biophysical research communications, 1991-04, Vol.176 (1), p.247-254

1991

Volltextzugriff (PDF)

Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 rat mammary carcinoma cells

British journal of cancer, 1993-01, Vol.67 (1), p.99-101

1993

Volltextzugriff (PDF)

Loss of keratin expression in anaplastic carcinoma cells due to posttranscriptional down-regulation acting in trans

Cancer research (Chicago, Ill.), 1992-12, Vol.52 (23), p.6603-6611

1992

Volltextzugriff (PDF)

1 – 25 von 239

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(217)
Mit Volltextzugriff
(188)

Publikationsform

Sprache

Englisch
(237)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(151)
Humans
(145)
Life Sciences & Biomedicine
(144)
Oncology
(88)
Biological And Medical Sciences
(66)
Female
(62)
Melanoma - Genetics
(59)
Male
(57)
Medical Sciences
(53)
Melanoma
(53)
Mutation
(50)
Middle Aged
(49)
Adult
(48)
Aged
(41)
Dermatology
(36)
Cell Biology
(34)
Tumors
(32)
Melanoma - Drug Therapy
(31)
Melanoma - Pathology
(30)
Tumors Of The Skin And Soft Tissue. Premalignant Lesions
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients

Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma

Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma : A consensus statement of the melanoma genetics consortium

Adjuvant therapy of cutaneous melanoma: the interferon debate

Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization

Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure

Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding

Loss of Alleles from the Distal Short Arm of Chromosome 1 Occurs Late in Melanoma Tumor Progression

Long-term Survival and Occasional Regression of Distant Melanoma Metastases after Adrenal Metastasectomy

A melanoma-associated germline mutation in exon 1β inactivates p14ARF

Loss of heterozygosity and homozygous deletions on 9p21-22 in melanoma

Cutaneous melanoma

CDKN2A (P16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas

Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells

The WDNM1 gene product is a novel member of the ‘four-disulphide core’ family of proteins

Dexamethasone decreases urokinase plasminogen activator mRNA stability in MAT 13762 rat mammary carcinoma cells

Loss of keratin expression in anaplastic carcinoma cells due to posttranscriptional down-regulation acting in trans

Suchergebnisse filtern